Compare EVLV & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EVLV | ANL |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.7M | 998.8M |
| IPO Year | 2020 | 2022 |
| Metric | EVLV | ANL |
|---|---|---|
| Price | $4.06 | $10.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $9.85 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 2.1M | 235.2K |
| Earning Date | 11-10-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $145,905,000.00 | N/A |
| Revenue This Year | $25.01 | $243.83 |
| Revenue Next Year | $20.02 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 40.48 | N/A |
| 52 Week Low | $4.02 | $0.88 |
| 52 Week High | $8.40 | $17.25 |
| Indicator | EVLV | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 23.98 | 30.35 |
| Support Level | N/A | $8.96 |
| Resistance Level | $5.86 | $12.49 |
| Average True Range (ATR) | 0.15 | 1.37 |
| MACD | -0.04 | -0.51 |
| Stochastic Oscillator | 4.47 | 1.73 |
Evolv Technologies Holdings Inc is a security technology company pioneering Artificial Intelligence (AI)-powered screening solutions designed to help create safer environments while maintaining efficient visitor flow and a positive visitor experience. It serves customers across a range of end markets, including education, healthcare, sports, live entertainment, tourist attractions, houses of worship, and industrial workplaces. The company operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.